Bioverativ And Bicycle Therapeutics Enter Into Strategic Research Collaboration To Develop Therapies For Haemophilia And Sickle Cell Disease

06 September 2017

Bicycle to receive an upfront payment of $10 million, with potential for future milestones WALTHAM, Mass. and CAMBRIDGE, U.K., September 6, 2017 – Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialisation of innovative therapies for haemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd., a biotechnology company […]

Continue Reading